Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) recently released financial results for the three and nine months ended September 30, 2017. Among other highlights from the third quarter, the company reported $43.4 million in cash, cash equivalents and marketable securities which provides a strong position for expansion plans for its high-tech Vanluven facility. Abcann also reported revenues of $614,000 for the nine months ended September 30, 2017, a considerable increase compared to $211,00 during the same period in 2016. Additionally, the company provided an update on operations, including the company’s strategy moving forward. “ABcann’s vision is to create a successful long-term business that creates superior products for our customers, value for our shareholders and a great workplace for our team. Our management team is working diligently to establish a strategic plan that will provide a roadmap for the Company’s long-term success in the fast-growing global cannabis industry,” ABcann CEO and director Barry Fishman stated in the news release.
ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centered on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products. The company is expanding its cultivation capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel. For more information, visit www.ABcannGlobal.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.